. 2015 Oct 1;31(10):1032–1037. doi: 10.1089/aid.2015.0138

Table 2.

Variation in Gag Cleavage Sites in Subtype C Viruses

			Gag cleavage sites
Patient number	Trial arm	Trial week failure (pre-PI)	MA/CA 128–137 VSQNY/PIVQN	CA/p2 359–368 KARVL/AEAMS	P2/NC 373–382 TXXIM/MQRGN	NC/p1 428–437 ERQAN/FLGKI	p1/p6 444–453 RPGNF/LQSRP
12	CT	Pre-PI	-----/-----	-----/-----	N-N--/-----	-----/-----	-----/-----
		Failure	G----/-----	-----/-----	NTN--/-----	-----/-----	-----/-----
13	CT	Pre-PI	-----/-----	-----/-----	N-NV-/-----	-----/-----	-----/--N--
		Failure	-----/-----	-----/-----	N-NV-/-----	-----/-----	-----/--N--
14	CT	Pre-PI	-----/-----	-----/-----	H-A--/--KS-	-----/-----	-----/--N--
		Failure	-----/-----	-----/-----	NTN--/--KS-	-----/-----	-----/--N--
15	bPImono	Pre-PI	I----/-----	-----/-----	NSN-L/---S-	-----/-----	-----/--N--
		Failure	-----/-----	-----/-----	NSN-L/---S-	---V-/-----	-----/--N--
16	CT	Pre-PI	-----/-----	-----/-----	NSN--/-----	-----/-----	-----/-----
		Failure	-----/-----	-----/-----	NSN--/-----	-----/-----	-----/-----
17	bPImono	Pre-PI	-----/-----	-----/-----	NSN--/----^NK	-----/-----	-----/--N--
		Failure	-----/-----	-----/-----	NSN--/-----	-----/-----	-----/--N-L
18	bPImono	Pre-PI	-----/-----	-----/-----	NN^NH--/---S-	-----/-----	-----/-----
		Failure	-----/-----	-----/-----	NNH--/---S-	-----/-----	-----/-----

The sequence at each of the Gag cleavage sites is shown for the seven patients infected with subtype C viruses, both at pre-PI therapy and at treatment failure time points. Sequences were compared with the HIV-1 group M consensus sequence⁹ using HXB2 numbering. Where no consensus residue was derived an X is present and mixed residues are shown in superscript letters. Clinical trial arm is shown: boosted PI monotherapy (bPImono) and continuation on combination therapy (CT).